ASH 2015 – Multiple Myeloma

Read More ›

Researchers reported on a study that assessed the clinical utility of minimal residual disease (MRD) monitoring in elderly patients with multiple myeloma (MM) included in the PETHEMA/GEM2010MAS65 trial. Read More ›

The ENDEAVOR study demonstrated that carfilzomib plus dexamethasone showed a significant improvement in median progression-free survival compared with bortezomib plus dexamethasone. This update examines outcomes in patients in high-risk cytogenetic subgroups. Read More ›

Read More ›

Read More ›

Results of a randomized, phase 2 study to determine the confirmed overall response rate in patients treated with ixazomib, an orally bioavailable proteasome inhibitor, for patients with relapsed multiple myeloma not refractory to bortezomib. Read More ›

Read More ›

Investigators examined the safety and efficacy of the combination of lenalidomide/ixazomib as a maintenance therapy after ASCT in a single-arm phase 2 study. Favorable results of this combination may warrant additional examination in a phase 3 study. Read More ›

The phase 1/2 Alliance study sought to evaluate the safety and preliminary efficacy of the combination of ixazomib/pomalidomide/dexamethasone in patients with double-refractory multiple myeloma compared with the approved combination of pomalidomide/dexamethasone. Here, they report the phase 1 portion of the Alliance study. Read More ›

Read More ›